SPDR® S&P® Biotech ETF

XBI

Key Features

  • The SPDR® S&P® Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P® Biotechnology Select IndustryTM Index (the "Index")
  • Seeks to provide exposure to the Biotechnology segment of the S&P TMI, which comprises the following sub-industries: Biotechnology
  • Seeks to track a modified equal weighted index which provides the potential for unconcentrated industry exposure across large, mid and small cap stocks
  • Allows investors to take strategic or tactical positions at a more targeted level than traditional sector based investing

Fund Information

As of 12/09/2019
Ticker Symbol XBI
Primary Benchmark S&P Biotechnology Select Industry Index
CUSIP 78464A870
Options Available Yes
Gross Expense Ratio

Gross Expense Ratio

The fund's total annual operating expense ratio. It is gross of any fee waivers or expense reimbursements. It can be found in the fund's most recent prospectus.

0.35%
Inception Date 01/31/2006
Investment Manager SSGA Funds Management, Inc.
Management Team Global Equity Beta Solutions
Distributor State Street Global Advisors Funds Distributors, LLC
Distribution Frequency Quarterly
Exchange NYSE ARCA EXCHANGE

Fund Documents

Fund Performance

MONTH END As of 11/30/2019 QUARTER END As of 09/30/2019
1 Month14.68%-5.14%
QTD22.68%-13.16%
YTD29.87%5.86%
1 Year14.71%-20.49%
3 Year14.49%4.96%
5 Year9.67%8.33%
10 Year19.15%15.94%
Inception
13.73%12.21%
Performance Disclosure

Performance quoted represents past performance, which is no guarantee of future results. Investment return and principal value will fluctuate, so you may have a gain or loss when shares are sold. Current performance may be higher or lower than that quoted. Performance of an index is not illustrative of any particular investment.  It is not possible to invest directly in an index.

The market price used to calculate the Market Value return is the midpoint between the highest bid and the lowest offer on the exchange on which the shares of the Fund are listed for trading, as of the time that the Fund's NAV is calculated. If you trade your shares at another time, your return may differ.

Fund Characteristics

As of 12/05/2019
Est. 3-5 Year EPS Growth

Estimated 3-5 Year EPS Growth 

Based on the underlying holdings of the fund. The actual earnings estimates for the underlying holdings are provided by FactSet, First Call, I/B/E/S Consensus, and Reuters and are used to calculate a mean 3-5 year EPS growth rate estimate.

21.76%
Number of Holdings 115
Price/Book Ratio

Price/Book Ratio

The weighted harmonic average of closing market price divided by the most recent reported book value for each security in the fund’s portfolio as calculated for the last twelve months.

5.12
Price/Earnings Ratio FY1

Price/Earnings Ratio FY1

The weighted harmonic average of current share price divided by the forecasted one year earnings per share for each security in the fund. Negative and positive outliers are included in the calculation.

17.79
Weighted Average Market Cap $13,282.06 M

Fund Market Price

As of 12/05/2019
Bid/Ask $93.24
Closing Price $93.28
Day High $94.52
Day Low $92.80
Exchange Volume (shares)

Exchange Volume (shares)

Represents the volume of shares traded on the ETF's primary exchange throughout the previous business day.

1,829,045
Premium/Discount

Premium/Discount to NAV

Shows the comparison of the daily net asset value (NAV) and the Midpoint of the closing bid/ask for each of the funds calculated as ((4PM Bid/Ask – Closing NAV)  /  Closing NAV * 100)

0.06%

Yields

As of 12/05/2019
30 Day SEC Yield

30 Day SEC Yield

(Also known as Standardized Yield) An annualized yield that is calculated by dividing the net investment income earned by the fund over the most recent 30-day period by the current maximum offering price.

-0.05%
Fund Dividend Yield

Fund Dividend Yield

The sum of the most recent 12 dividends within the past 365 days divided by Net Asset Value per share, expressed as a percentage.

0.02%
Index Dividend Yield

Index Dividend Yield

The weighted average of the underlyings' indicated annual dividend divided by price, expressed as a percentage.

0.19%

Fund Net Asset Value

NAV

The market value of a mutual fund's or ETFs total assets, minus liabilities, divided by the number of shares outstanding.

As of 12/05/2019
NAV

NAV

The market value of a mutual fund's or ETFs total assets, minus liabilities, divided by the number of shares outstanding.

$93.19
Shares Outstanding 46.38 M
Total Net Assets $4,321.78 M

Index Characteristics

As of 12/05/2019
Est. 3-5 Year EPS Growth 21.76%
Number of Holdings 115
Price/Cash Flow 18.15
Price/Earnings 16.70
Price/Earnings Ratio FY1 17.79

Fund Net Cash Amount

As of 12/05/2019
Net Cash Amount -$1,147,991.01

Index Statistics

As of 12/05/2019
Weighted Average Market Cap $13,286.07 M
Average Size
Mean $7,192.51 M
Median $1,761.99 M
Size Range
Largest $139,159.05 M
Smallest $278.46 M

Purchase Information

Buying and Selling ETFs

ETFs are flexible and easy to trade. Investors buy and sell them like stocks, typically through a brokerage account. Investors can also employ traditional stock trading techniques; including stop orders, limit orders, margin purchases, and short sales using ETFs. They are listed on major US Stock Exchanges.

ETFs are subject to risk similar to those of stocks including those regarding short-selling and margin account maintenance.

Ordinary brokerage commissions apply.

Performance Chart

Fund Before Tax Fund After Tax
Annualized
As of 1 Month QTD YTD 1 Year 3 Year 5 Year 10 Year Since
Inception
01/31/2006
Month End
NAV 11/30/2019 14.68% 22.68% 29.87% 14.71% 14.49% 9.67% 19.15% 13.73%
Market Value 11/30/2019 14.65% 22.64% 29.98% 14.67% 14.47% 9.65% 19.15% 13.72%
Return after Taxes on Distributions 11/30/2019 14.68% 22.68% 29.87% 14.70% 14.44% 9.55% 19.03% 13.61%
Return after Taxes on Distributions and Sale of Fund Shares 11/30/2019 8.69% 13.42% 17.68% 8.71% 11.36% 7.61% 16.49% 11.85%
S&P Biotechnology Select Industry Index 11/30/2019 14.72% 22.66% 29.98% 14.82% 14.53% 9.53% 19.01% 13.73%
Quarter End
NAV 09/30/2019 -5.14% -13.16% 5.86% -20.49% 4.96% 8.33% 15.94% 12.21%
Market Value 09/30/2019 -5.10% -13.11% 5.99% -20.43% 4.96% 8.31% 15.95% 12.21%
Return after Taxes on Distributions 09/30/2019 -5.14% -13.17% 5.86% -20.50% 4.92% 8.21% 15.81% 12.09%
Return after Taxes on Distributions and Sale of Fund Shares 09/30/2019 -3.04% -7.79% 3.47% -12.13% 3.82% 6.53% 13.54% 10.44%
S&P Biotechnology Select Industry Index 09/30/2019 -5.11% -13.15% 5.96% -20.41% 5.00% 8.16% 15.79% 12.22%
Fund Before Tax Fund After Tax
Annualized
As of 1 Month QTD YTD 1 Year 3 Year 5 Year 10 Year Since
Inception
01/31/2006
Month End
NAV 11/30/2019 14.68% 22.68% 29.87% 14.71% 14.49% 9.67% 19.15% 13.73%
Market Value 11/30/2019 14.65% 22.64% 29.98% 14.67% 14.47% 9.65% 19.15% 13.72%
Return after Taxes on Distributions 11/30/2019 14.68% 22.68% 29.87% 14.70% 14.44% 9.55% 19.03% 13.61%
Return after Taxes on Distributions and Sale of Fund Shares 11/30/2019 8.69% 13.42% 17.68% 8.71% 11.36% 7.61% 16.49% 11.85%
S&P Biotechnology Select Industry Index 11/30/2019 14.72% 22.66% 29.98% 14.82% 14.53% 9.53% 19.01% 13.73%
Quarter End
NAV 09/30/2019 -5.14% -13.16% 5.86% -20.49% 4.96% 8.33% 15.94% 12.21%
Market Value 09/30/2019 -5.10% -13.11% 5.99% -20.43% 4.96% 8.31% 15.95% 12.21%
Return after Taxes on Distributions 09/30/2019 -5.14% -13.17% 5.86% -20.50% 4.92% 8.21% 15.81% 12.09%
Return after Taxes on Distributions and Sale of Fund Shares 09/30/2019 -3.04% -7.79% 3.47% -12.13% 3.82% 6.53% 13.54% 10.44%
S&P Biotechnology Select Industry Index 09/30/2019 -5.11% -13.15% 5.96% -20.41% 5.00% 8.16% 15.79% 12.22%
Swipe to view all columns
Performance Disclosure

Performance quoted represents past performance, which is no guarantee of future results. Investment return and principal value will fluctuate, so you may have a gain or loss when shares are sold. Current performance may be higher or lower than that quoted. Performance of an index is not illustrative of any particular investment.  It is not possible to invest directly in an index.

The market price used to calculate the Market Value return is the midpoint between the highest bid and the lowest offer on the exchange on which the shares of the Fund are listed for trading, as of the time that the Fund's NAV is calculated. If you trade your shares at another time, your return may differ.

Gross Expense Ratio: 0.35%

Performance Graphs

Month End as of 11/30/2019

Fund Inception Date: 01/31/2006

Index Inception Date: 01/31/2006

<performance fundName="SPDR&lt;sup&gt;®&lt;/sup&gt; S&amp;P&lt;sup&gt;®&lt;/sup&gt; Biotech ETF" bmarkName="S&amp;P Biotechnology Select Industry Index"><funds><field>1 Month</field><fund>14.68</fund><index>14.72</index><secondIndex></secondIndex><tertiaryIndex></tertiaryIndex></funds><funds><field>QTD</field><fund>22.68</fund><index>22.66</index><secondIndex></secondIndex><tertiaryIndex></tertiaryIndex></funds><funds><field>YTD</field><fund>29.87</fund><index>29.98</index><secondIndex></secondIndex><tertiaryIndex></tertiaryIndex></funds><funds><field>1 YR</field><fund>14.71</fund><index>14.82</index><secondIndex></secondIndex><tertiaryIndex></tertiaryIndex></funds><funds><field>3 YR</field><fund>14.49</fund><index>14.53</index><secondIndex></secondIndex><tertiaryIndex></tertiaryIndex></funds><funds><field>5 YR</field><fund>9.67</fund><index>9.53</index><secondIndex></secondIndex><tertiaryIndex></tertiaryIndex></funds><funds><field>10 YR</field><fund>19.15</fund><index>19.01</index><secondIndex></secondIndex><tertiaryIndex></tertiaryIndex></funds><funds><field>Inception</field><fund>13.73</fund><index>13.73</index><secondIndex></secondIndex><tertiaryIndex></tertiaryIndex></funds></performance>

Quarter End as of 09/30/2019

Fund Inception Date: 01/31/2006

Index Inception Date: 01/31/2006

<performance fundName="SPDR&lt;sup&gt;®&lt;/sup&gt; S&amp;P&lt;sup&gt;®&lt;/sup&gt; Biotech ETF" bmarkName="S&amp;P Biotechnology Select Industry Index"><funds><field>1 Month</field><fund>-5.14</fund><index>-5.11</index><secondIndex></secondIndex><tertiaryIndex></tertiaryIndex></funds><funds><field>QTD</field><fund>-13.16</fund><index>-13.15</index><secondIndex></secondIndex><tertiaryIndex></tertiaryIndex></funds><funds><field>YTD</field><fund>5.86</fund><index>5.96</index><secondIndex></secondIndex><tertiaryIndex></tertiaryIndex></funds><funds><field>1 YR</field><fund>-20.49</fund><index>-20.41</index><secondIndex></secondIndex><tertiaryIndex></tertiaryIndex></funds><funds><field>3 YR</field><fund>4.96</fund><index>5.00</index><secondIndex></secondIndex><tertiaryIndex></tertiaryIndex></funds><funds><field>5 YR</field><fund>8.33</fund><index>8.16</index><secondIndex></secondIndex><tertiaryIndex></tertiaryIndex></funds><funds><field>10 YR</field><fund>15.94</fund><index>15.79</index><secondIndex></secondIndex><tertiaryIndex></tertiaryIndex></funds><funds><field>Inception</field><fund>12.21</fund><index>12.22</index><secondIndex></secondIndex><tertiaryIndex></tertiaryIndex></funds></performance>

Fund Top Holdings

Subject to change.

As of 12/05/2019
Name Weight Total Mkt Cap M Shares Held
Arrowhead Pharmaceuticals Inc. 3.21 % $ 6,533.86 2,115,421
Medicines Company 2.57 % $ 6,706.39 1,326,540
Intercept Pharmaceuticals Inc. 2.55 % $ 3,920.76 919,534
Seattle Genetics Inc. 2.43 % $ 20,079.58 896,971
Alnylam Pharmaceuticals Inc 2.18 % $ 13,850.40 756,853
Global Blood Therapeutics Inc 2.07 % $ 4,586.59 1,172,365
Regeneron Pharmaceuticals Inc. 1.92 % $ 39,761.19 224,935
Sarepta Therapeutics Inc. 1.87 % $ 8,196.75 736,687
Vertex Pharmaceuticals Incorporated 1.87 % $ 57,362.45 362,122
Biogen Inc. 1.85 % $ 54,022.53 267,693

Index Top Holdings

As of 12/05/2019
Name Weight Total Mkt Cap M
Arrowhead Pharmaceuticals Inc. 3.21 % $6,533.86
Medicines Company 2.58 % $6,706.39
Intercept Pharmaceuticals Inc. 2.55 % $3,920.76
Seattle Genetics Inc. 2.43 % $20,079.58
Alnylam Pharmaceuticals Inc 2.18 % $13,850.40
Global Blood Therapeutics Inc 2.07 % $4,586.59
Regeneron Pharmaceuticals Inc. 1.92 % $39,761.19
Sarepta Therapeutics Inc. 1.88 % $8,196.75
Vertex Pharmaceuticals Incorporated 1.87 % $57,362.45
Biogen Inc. 1.86 % $54,022.53

Fund Sub-Industry Allocation

As of 12/05/2019
<?xml version="1.0" encoding="UTF-8"?><component><asOfDate>12/05/2019</asOfDate><overrideLabel>Fund Sub-Industry Allocation </overrideLabel><code>FUND_SECTOR_ALLOCATION</code><attributes><attribute><rawValue>98.37</rawValue><value>98.37%</value><label>Biotechnology</label><order>1</order></attribute><attribute><rawValue>1.63</rawValue><value>1.63%</value><label>Life Sciences Tools &amp; Services</label><order>2</order></attribute></attributes></component>

Index Sub-Industry Allocation

As of 12/05/2019
<?xml version="1.0" encoding="UTF-8"?><component><asOfDate>12/05/2019</asOfDate><overrideLabel>Index Sub-Industry Allocation </overrideLabel><code>BMARK_SECTOR_ALLOCTAION</code><attributes><attribute><rawValue>98.37</rawValue><value>98.37%</value><label>Biotechnology</label><order>1</order></attribute><attribute><rawValue>1.63</rawValue><value>1.63%</value><label>Life Sciences Tools &amp; Services</label><order>2</order></attribute></attributes></component>

In general, ETFs can be expected to move up or down in value with the value of the applicable index. Although ETF shares may be bought and sold on the exchange through any brokerage account, ETF shares are not individually redeemable from the Fund. Investors may acquire ETFs and tender them for redemption through the Fund in Creation Unit Aggregations only. Please see the prospectus for more details.

After-tax returns are calculated based on NAV using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on the investor's tax situation and may differ from those shown. The after-tax returns shown are not relevant to investors who hold their fund shares through tax-deferred arrangements such as 401(k) plans or individual retirement accounts.

Performance of an index is not illustrative of any particular investment. It is not possible to invest directly in an index.

As with all stocks, you may be required to deposit more money or securities into your margin account if the equity, including the amount attributable to your ETF shares, declines.

Unless Otherwise noted all information contained herein is that of the SPDR S&P Biotech ETF.

The S&P Select Industry series is designed to measure the performance of narrow GICS (Global Industry Classification Standard) sub-industries. The S&P Biotech Select Industry Index is an equal-weighted index that draws constituents from the Biotechnology segment of the S&P TMI. Liquidity and market capitalization screens are applied to the index to ensure investability.

Global Equity Beta Solutions

Co-Head, Global Equity Beta Solutions Michael J. Feehily Senior Managing Director Show BioHide Bio

Mike is a Senior Managing Director and the Head of Global Equity Beta Solutions in the Americas. He is also a member of the Senior Leadership Team and is a voting member on the firm's Trade Management Oversight Committee and the North America Product Committee.

Mike rejoined SSGA in 2010 after spending four years in State Street Global Markets where he helped to build the Global Exposure Solutions business. This group created and managed portfolios that were designed to meet the short-term market exposure needs of our institutional clients. Prior to this Mike had been Head of the US Passive Equity Team within SSGA, which he originally joined in 1997. He began his career at State Street within the Global Services division in 1992.

Mike received a Bachelor of Science Degree from Babson College in Finance, Investments, and Economics. He received an MBA in Finance from Bentley College and also earned the Chartered Financial Analyst designation. He is a member of the CFA Institute and the Boston Security Analysts Society. Mike is also a former member of the Russell Index Client Advisory Board.

Deputy Head of GEBS - Americas Karl A. Schneider Managing Director Show BioHide Bio

Karl Schneider, CAIA, is a Managing Director of SSGA and Deputy Head of Global Equity Beta Solutions (GEBS) in the Americas. He also serves as a senior portfolio manager for a number of the group's passive equity portfolios. Previously within GEBS, he served as a portfolio manager and product specialist for US equity strategies and synthetic beta strategies, including commodities, buy/write, and hedge fund replication. He is also a member of the S&P Dow Jones US Equities Index Advisory Panel.

Prior to joining the GEBS team, Mr. Schneider worked as a portfolio manager in SSGA's Currency Management Group, managing both active currency selection and traditional passive hedging overlay portfolios. He joined SSGA in 1997.

Mr. Schneider holds a BS in Finance and Investments from Babson College and also an MS in Finance from Boston College. He has earned the Chartered Alternative Investment Analyst designation and is a member of the CAIA Association.

Senior Portfolio Manager Ray Donofrio Vice President Show BioHide Bio

Raymond Donofrio is a Vice President within SSGA and a Senior Portfolio Manager in the Global Equity Beta Solutions Group. Ray is currently responsible for managing various equity index funds, with both domestic and international strategies.

Prior to his current role, Ray was an Analyst for SSGA's Strategy and Research group within the Global ETF Group. He began his career as an associate within the Investment Operations team at SSGA. He supported the Portfolio Managers of the Global Equity Beta Solutions team, mainly focusing on international strategies.

Ray received his bachelor of science degree in financial services from Bryant University, and his MBA with a concentration in Finance from Boston University's Questrom School of Business.

After Tax Returns

After-tax returns are calculated using the historical highest individual federal marginal income tax rates, and do not reflect the impact of state and local taxes. Actual after tax returns depend on the investor's tax situation and may differ from those shown, and the after-tax returns shown are not relevant to investors who hold their fund shres through tad deferred arrangements such as 401(k) plans or individual retiredment accounts. After tax returns may not take into account year end tax adjustments, which are calculated only at the end of each tax year. The after tax returns could differ after year end tax adjustments are accounted for.

S&P Biotechnology Select Industry Index

The S&P Biotechnology Select IndustryTM represents the biotechnology segment of the S&P Total Market Index ("S&P TMI"). The S&P TMI is designed to track the broad U.S. equity market. The biotechnology segment of the S&P TMI comprises the Biotechnology sub-industry. The Index is modified equal weighted.

Important Risk Information

In general, ETFs can be expected to move up or down in value with the value of the applicable index. Although ETF shares may be bought and sold on the exchange through any brokerage account, ETF shares are not individually redeemable from the Fund.

Investors may acquire ETFs and tender them for redemption through the Fund in Creation Unit Aggregations only. Please see the prospectus for more details.

Because of their narrow focus, sector funds tend to be more volatile than funds that diversify across many sectors and companies.

Non-diversified funds that focus on a relatively small number of securities tend to be more volatile than diversified funds and the market as a whole.

Passively managed funds hold a range of securities that, in the aggregate, approximates the full Index in terms of key risk factors and other characteristics. This may cause the fund to experience tracking errors relative to performance of the index.

While the shares of ETFs are tradable on secondary markets, they may not readily trade in all market conditions and may trade at significant discounts in periods of market stress.

ETFs trade like stocks, are subject to investment risk, fluctuate in market value and may trade at prices above or below the ETFs net asset value. Brokerage commissions and ETF expenses will reduce returns.

Before investing, consider the funds' investment objectives, risks, charges and expenses. To obtain a prospectus or summary prospectus which contains this and other information, call 1-866-787-2257, download a prospectus or summary prospectus now, or talk to your financial advisor. Read it carefully before investing.

Glossary

Premium Discount to NAV

As of 12/05/2019
Ticker NAV Close Bid/Ask Mid Pt Premium/ Discount
SPDR® S&P® Biotech ETF XBI $93.19 $93.28 $93.24 0.06%
Download Fund Data

x axis: # of days y axis: # Premium/Discount percentage

The above information is provided to show the comparison of the daily net asset value (NAV) and the Midpoint of the closing bid/ask for each of the funds.

Before investing, consider the funds' investment objectives, risks, charges and expenses. To obtain a prospectus or summary prospectus which contains this and other information, call 1-866-787-2257, download a prospectus or summary prospectus now, or talk to your financial advisor. Read it carefully before investing.

Centralized Systematic Valuation Aggregated Cash Flow (ACF) File

This information provided is calculated by Bloomberg Finance L.P., a third party not affiliated with SSGA. Neither SSGA nor its affiliates assume any liability for or guarantee the timeliness, accuracy and completeness of the information provided. The information provided is as of the date indicated and is subject to change.

This analysis or any portion thereof may not be revised or changed in any way, reprinted, sold or redistributed without the written consent of SSGA.

This cash flow table and the data contained herein (together, "Content") is provided for informational purposes only, on an "as is" basis. No source of Content, or any of its affiliates (each a "Source"), makes any warranty, express or implied, that the Content is accurate, complete or error-free, and it should not be relied upon as such. No Source guarantees the timeliness, reliability, performance, continued availability, or currency of the Content or any results obtained therefrom. No Source shall be liable for any damages, including without limitation, any special, punitive, indirect, incidental or consequential damages, or any lost profits, arising from the use of or reliance on the Content, even if advised of the possibility of such damages. Nothing in the Content shall constitute or be construed as an offering of financial instruments by any Source, or as investment advice or recommendations by such entities of an investment strategy or whether or not to "buy", "sell" or "hold" an investment.

I AGREE CLOSE